Chimerix un­rolls ear­ly win for glioma drug picked up ear­li­er this year in ac­qui­si­tion

Small biotech Chimerix made a big bet ear­ly this year when it bought out On­co­ceu­tics and lead drug ONC201 for gliomas. Now, that in­vest­ment is show­ing a bit more promise.

Ear­ly da­ta from a Phase II study of ONC201 showed a 20% ORR in 50 pa­tients above the age of 2 who have re­ceived ra­di­a­tion at least 90 days pri­or to en­roll­ment and dis­played ev­i­dence of pro­gres­sive dis­ease, and cer­tain oth­er cri­te­ria, Chimerix said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER